As the primary component of the amyloid plaques seen in the brains of Alzheimer patients, amyloid- (A) refers to peptides of 36–43 amino acids that are crucially involved in Alzheimer's disease. The amyloid precursor protein (APP), which is cut by specific enzymes to produce A, produces the peptides. Amyloid molecules can group together to create a variety of flexible, soluble oligomers.A amyloid-peptide buildup results from excessive A production or malfunctioning clearance mechanisms. Amyloid- forms diffuse and neuritic plaques in the parenchyma and blood vessels by self-aggregating into oligomers of various sizes. Strong synaptotoxins, proteasome inhibition, mitochondrial inhibition, alteration of intracellular Ca2+ levels, and induction of inflammatory processes are all characteristics of amyloid-oligomers and plaques. Neuronal dysfunction is also thought to be influenced by the loss of A's typical physiological functions.
Structure | Cat No. | Product Name | CAS No. | Product Description |
---|---|---|---|---|
V71438 | 2,3-Dehydrosilybin A | 25166-14-7 | 2,3-Dehydrosilybin A is a longevity-promoting and anti-aggregation compound. | |
V71371 | 2-Hydroxy-5-(phenyldiazenyl)benzoic acid-d5 | 1331662-16-8 | 2-Hydroxy-5-(phenyldiazenyl)benzoic acid-d5 is deuterated labeled 2-Hydroxy-5-(phenyldiazenyl)benzoic acid. | |
V77650 | 5-FAM-β-Amyloid (1-42), human TFA (5-FAM-Amyloid β-peptide (1-42) (human) TFA) | 5-FAM-β-Amyloid (1-42), human (5-FAM-Amyloid β-peptide (1-42) (human) TFA is a 5-FAM-labeled β-Amyloid (1-42), human (TFA). | ||
V86199 | 5-FAM-β-Amyloid (1-42), human Tris (5-FAM-Amyloid β-peptide (1-42) (human) Tris) | |||
V83543 | 6′-Methyl paeonol | 6540-66-5 | ||
V71443 | 7-Deoxy-trans-dihydronarciclasine | 145987-74-2 | 7-Deoxy-trans-dihydronarciclasine is an alkaloid and an inhibitor (blocker/antagonist) of tobacco mosaic virus (TMV) (IC50= 1.80 μM). | |
V71439 | [Ala28]-β Amyloid(25-35) (β(25-35)KA) | 173993-86-7 | [Ala28]-β Amyloid(25-35) (β(25-35)KA) is an electroneutral mutant peptide of Aβ(25-35) that accelerates the aggregation of firefly luciferase. | |
V71378 | [Arg6]-β-Amyloid (1-40), england mutation | 1802084-26-9 | [Arg6]-β-Amyloid (1-40), england mutation is a biologically active peptide. | |
V77472 | [Arg6]-β-Amyloid (1-42), england mutation | [Arg6]-β-Amyloid (1-42), england mutation is a biologically active peptide. | ||
V71392 | [Asn23] β-Amyloid (1-40), Iowa mutation | 374796-72-2 | [Asn23] β-Amyloid (1-40), Iowa mutation is a biologically active peptide. | |
V77473 | [Asn23]-beta-Amyloid (1-42), iowa mutation | [Asn23]-beta-Amyloid (1-42), iowa mutation is a biologically active peptide. | ||
V92286 | [D-Ser14]-Humanin | 570382-85-3 | [D-Ser14]-Humanin is a biologically active peptide in which the Ser14 residue of humanin is changed from L-form to D-form. | |
V71399 | AC 253 | 151804-79-4 | AC 253 is an antagonist of amylin, inhibiting 125I-adrenomedullin binding, with IC50 of 25 nM. | |
V71397 | Acetly-β Amyloid(15-20), Amide | 189064-06-0 | Acetly-β Amyloid (15-20), Amide is a polypeptide fragment. | |
V71434 | Acetyl-Amyloid β-Protein (1-6) amide | 903883-22-7 | Acetyl-Amyloid β-Protein (1-6) amide is a hexapeptide that contains potential copper(II) binding sites. | |
V71431 | Acetyl-Tau Peptide (273-284)amide | 1684399-52-7 | Acetyl-Tau Peptide (273-284) amide is an acetylated Tau peptide fragment. | |
V87778 | AChE-IN-59 | 2957916-86-6 | AChE-IN-59 (compounds 3b) is an inhibitor of AChE with an IC50 value of 0.05 µM. | |
V87780 | AChE-IN-63 | 876685-78-8 | AChE-IN-63 is an inhibitor of hAChE, hBChE, and hBACE-1 (IC50=0.103 μM (hAChE), 10 μM (hBChE), and 1.342 μM (hBACE-1)). | |
V79836 | AChE/Aβ-IN-1 | AChE/Aβ-IN-1 (compound 32) is a potent oral acetylcholinesterase (AChE) inhibitor (antagonist) with IC50 of 86 nM and an NMDA receptor (GluN1-1b/GluN2B subunit combination) antagonist. | ||
V79835 | AChE/Aβ-IN-2 | AChE/Aβ-IN-2 (compound 32) is a potent oral acetylcholinesterase (AChE) inhibitor (antagonist) with IC50 of 86 nM and an NMDA receptor (GluN1-1b/GluN2B subunit combination) antagonist. |